| Overview |
| bs-9842R |
| phospho-LEF1 (Ser42) Polyclonal Antibody |
| WB, IHC-P, IHC-F, IF |
| This antibody will recognize LEF1(Ser40) in mouse and rat |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human LEF1 around the phosphorylation site of Ser42 |
| Ser42 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 51176 |
| Q9UJU2 |
| Nucleus |
| LEF-1; TCF10; TCF7L3; TCF1ALPHA; Lymphoid enhancer-binding factor 1; T cell-specific transcription factor 1-alpha; TCF1-alpha; LEF1 |
| Participates in the Wnt signaling pathway. Activates transcription of target genes in the presence of CTNNB1 and EP300. May play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha enhancer function. Binds DNA in a sequence-specific manner. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1 (By similarity). Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
IFIHC-P1:50-200 |
| IF |
|